Adverse events raise concerns over safety of new hepatitis C drugs

Newer antiviral drugs for treating hepatitis C virus (HCV) may be associated with liver failure and other severe side effects, a non-profit drug safety group in the US has warned in a report released on 25 January.1

The report, by the Institute for Safe Medication Practices, is based on a review of adverse drug event reports submitted to the US Food and Drug Administration that were associated with new direct acting HCV antivirals.1

The drugs found to be associated with adverse drug events included: daclatasvir …